Chronic Lymphocytic Leukemia (CLL) research hub
8 indexed studies · 4 currently recruiting
- recruitingPHASE2
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
This study looks at a new way to re-treat a type of blood cancer called CLL when it returns. It uses two approved medicines, venetoclax and obinutuzumab, in adults who have had previous venetoclax treatment.
United States · Australia · Austria - recruitingPHASE1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This study is testing a new medicine, NX-5948, for adults with certain types of blood cancer that have come back or not responded well to previous treatments. It aims to find out if the medicine is safe and helps fight the cancer, starting with small doses and gradually increasing.
United States · France · Italy - recruiting
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
This study looks back at how well a medicine called acalabrutinib worked for people in the UK with Chronic Lymphocytic Leukaemia (CLL) who took it first, as part of an early access programme. Researchers want to understand their experiences and treatment outcomes in real life.
United Kingdom - recruitingPHASE2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This study looks at a new drug, NX-5948, for adults with specific types of blood cancer (CLL or SLL) that have come back or not responded to previous treatments. It aims to see how well and how safely this new drug works.
United States · France · Italy - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies
This study is testing a new drug, PRT2527, sometimes combined with other medicines. It's for adults with certain blood cancers like leukaemia and lymphoma that haven't responded to previous treatments. It aims to see if the new drug is safe and how it works.
Germany · Poland · Italy - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
This study compares two treatments for chronic lymphocytic leukaemia (CLL) in patients who haven't had treatment before and have other health issues. It's looking at how well a new combination of medicines works against a standard treatment, aiming to find safer and more effective options.
Bulgaria · Estonia · Romania - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation
This study compares two treatments for newly diagnosed Chronic Lymphocytic Leukemia (CLL). It looks at how well a combination of venetoclax and obinutuzumab works against standard treatments (FCR/BR) to reduce tiny amounts of cancer cells and improve overall health.
Spain · France · Italy - authorisedTherapeutic use (Phase IV)
ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
This study looks at how your skin reacts to certain advanced cancer medicines, called biotherapies. We're finding the strongest dose that doesn't cause a skin reaction in most people when tested on the skin, to make these treatments safer.
France